CALDEIRÃO DE BOLSA

Como a nossa Bolsa anda a ser vendida pelos estrangeiros e fundos... eu tambem sai de alguns titulos nacionais para reforçar noutros q sigo e apresentam boas persêctivas como neste caso a EXEL (nasdaq) que ja subiu significativa desde o meu post, mas parece q quer continuar ...
exel esta na minha linha de mira para reforço.

Why the Exelixis Cancer Trial News Matters This Time
24/7 Wall St. By Paul Ausick
July 14, 2014 4:24 PM

Cancer treatment developer Exelixis Inc. (EXEL) is trading very heavy volume today and getting a sharp price boost following a positive result in a phase 3 pivotal trial of a combination of drugs including the company’s cobimetinib delivered a statistically significant increase in progression-free survival for a certain type of melanoma. The drug was used in conjunction with vemurafenib in a trial led by Exelixis partner Genentech.

Exelixis discovered the cobimetinib drug and entered a co-development agreement with Genentech in 2006 which paid Exelixis initial upfront and milestone payments for signing the agreement and submitting the investigational new drug application. Exelixis completed the first phase developing the drug before turning the development work over to Genentech